Fiche traitement
Oxaliplatin
AbbVie • Cancer, Parkinson
Suivi actif
Phase 2
Résumé
Oxaliplatin est développé par AbbVie. Le traitement est actuellement en Phase 2. Il est associé à Cancer, Parkinson. Son objectif thérapeutique principal est À vérifier. Le statut actuel est : suivi actif.
À vérifier
À vérifier
Phase 2
AbbVie
United States, Australia, Austria, Brazil, Canada, Czechia, France, Greece, …
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab.
Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. Participants will then be randomized into 3 groups called treatment arms where one group will receive one of two optimized doses of telisotuzumab adizutecan from the dose escalation phase with FOLFOX and bevacizumab or 5FU/LV and panitumumab, or a comparator of FOLFOX and bevacizumab or panitumumab. Approximately 390 adult participants with mCRC will be enrolled in the study in 100 sites worldwide.
In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive FOLFOX or receive 5FU/LV, but with one of two optimized doses of telisotuzumab adizutecan, or a comparator of FOLFOX and bevacizumab/pantitumumab. The study will run for a duration of approximately 6 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
2026-09-10
Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique
Phase 2
Début phase actuelle
Non disponible dans les sources synchronisées
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé
Objectif scientifique de l’étude
classification automatique vérifiable
À vérifier
Confiance automatique : 0%
Ce pourcentage n’est pas une probabilité de succès clinique.
Il mesure uniquement la force de la classification automatique de l’objectif scientifique. Le calcul part de 45 points, ajoute 7 points par unité de poids du mot-clé le plus fortement détecté, puis est plafonné à 95 %. Exemple : un score maximal de 2 donne 45 + (2 × 7) = 59 %.
Ce score est heuristique et doit être vérifié dans le protocole ou une publication.
Description affichée depuis l’essai compatible NCT06820463, afin d’éviter le mélange entre plusieurs indications d’une même molécule.
Contrôle de cohérence : 85/100
L’objectif est absent ou classé « Autre » et doit être recalculé à partir du protocole.
Transparence et qualité de la fiche
données vérifiablesClassificationÀ vérifier
Confiance de la fiche85 %
Source principaleSource officielle ou publication indexée
Dernière vérification2026-09-10
Anomalies détectées1
Validation humaineValidation humaine non effectuée
Donnée issue d’une source
Donnée normalisée automatiquement
Interprétation algorithmique
Classification scientifique multi-axes
ne pas confondre statut et résultatÉtat de l’étudeRecrutement en cours
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable
Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.
Indicateurs factuels
sans score subjectifPhase enregistréePhase 2
Études associées5
Publications associées16
Statut consolidéSuivi actif
Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.
Historique factuel de la molécule
33 événement(s) daté(s)Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.
| Date | Événement | Source |
|---|---|---|
| 2012-01-01 | Début de l’étudeNCT02867397 | Registre d’essai clinique |
| 2015-08-01 | Fin de l’étude prévue / enregistréeNCT02867397 | Registre d’essai clinique |
| 2025-03-05 | Début de l’étudeNCT06806033 | Registre d’essai clinique |
| 2025-04-24 | Début de l’étudeNCT06820463 | Registre d’essai clinique |
| 2026-03-01 | Début de l’étudeNCT07504198 | Registre d’essai clinique |
| 2026-05-06 | Début de l’étudeNCT07549412 | Registre d’essai clinique |
| 2026-07-08 | Création de l’enregistrementNCT02867397 | Registre d’essai clinique |
| 2026-07-08 | PublicationClinical use of trastuzumab combined with different chemotherapy regimens in multi-line treatment of advanced human epidermal growth factor receptor 2-positive gastric cancer: A case report. | Oncology letters |
| 2026-07-08 | PublicationCase Report: Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma. | Frontiers in oncology |
| 2026-07-08 | PublicationGastric Cancer Treated with 5-Fluorouracil following Discontinuation of Adjuvant S1 plus Docetaxel and Capecitabine plus Oxaliplatin due to Drug-Induced Acute Pancreatitis: A Case Report. | Case reports in oncology |
| 2026-07-08 | PublicationThe Landmark Series: Neoadjuvant Therapy for Patients with Resectable Gastroesophageal Junction Adenocarcinomas. | Annals of surgical oncology |
| 2026-07-10 | PublicationReal-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study. | BMJ oncology |
| 2026-07-13 | Dernière mise à jour du registreNCT02867397 | Registre d’essai clinique |
| 2026-07-14 | PublicationSalvage ultra-low-dose radiotherapy for conjunctival mantle cell lymphoma - a case report and literature review. | Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology |
| 2026-07-14 | PublicationBreakthrough reactions in pediatric chemotherapeutic desensitization: Outcomes and associated risk factors. | Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology |
| 2026-08-13 | PublicationResveratrol Modulates Phosphatidylcholine Metabolism-Related Enzymes and Enhances Chemosensitivity in Colorectal Cancer Models. | International journal of molecular sciences |
| 2026-08-13 | PublicationCost-effectiveness analysis of liposomal Irinotecan in combination with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas in Greece. | Expert review of pharmacoeconomics & outcomes research |
| 2026-08-16 | Création de l’enregistrementNCT06806033 | Registre d’essai clinique |
| 2026-08-16 | Création de l’enregistrementNCT07549412 | Registre d’essai clinique |
| 2026-08-16 | PublicationSingle-Institution Outcomes of Neoadjuvant Gemcitabine and Nab-Paclitaxel Combination in Borderline Resectable Pancreatic Adenocarcinoma: A Three-Year Retrospective Audit. | Cureus |
| 2026-08-16 | PublicationAddition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network. | Lancet (London, England) |
| 2026-08-16 | PublicationBacterial Ghosts as Innovative Transport Vehicles for Platinum-Based Anticancer Drugs. | ChemMedChem |
| 2026-08-16 | PublicationPooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies. | Oncoimmunology |
| 2026-08-16 | PublicationInsights into neuropathic pain: From disease models to therapeutic interventions. | Neuroscience and biobehavioral reviews |
| 2026-08-16 | PublicationDomain-specific cognitive impairments following oxaliplatin and 5-fluorouracil treatment in rats: A preclinical study. | Behavioural brain research |
| 2026-08-16 | PublicationRandomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer. | Annals of medicine |
| 2026-08-26 | Création de l’enregistrementNCT07504198 | Registre d’essai clinique |
| 2026-09-10 | Dernière mise à jour des donnéesOxaliplatin | Biomedical Watch |
| 2026-09-14 | Création de l’enregistrementNCT06820463 | Registre d’essai clinique |
| 2027-05-01 | Fin de l’étude prévue / enregistréeNCT07504198 | Registre d’essai clinique |
| 2028-04-01 | Fin de l’étude prévue / enregistréeNCT06820463 | Registre d’essai clinique |
| 2029-03-30 | Fin de l’étude prévue / enregistréeNCT06806033 | Registre d’essai clinique |
| 2029-10-16 | Fin de l’étude prévue / enregistréeNCT07549412 | Registre d’essai clinique |
Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés
5 essai(s)
Début phase actuelle
Non disponible dans les sources synchronisées
| NCT | Titre | Phase | Statut administratif | Pays | Sponsor |
|---|---|---|---|---|---|
| NCT06820463 | AndroMETa-CRC — A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer | Phase 2 | RECRUITING | United States, Australia, Austria, Brazil, Canada, Czechia, France, Greece, Israel, Japan, Puerto Rico, Spain, Taiwan, United Kingdom | AbbVie |
| NCT07504198 | Neuroprotection of Memantine and Rosuvastatin | Phase 2/3 | NOT_YET_RECRUITING | Egypt | Tanta University |
| NCT06806033 | A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | Phase 2 | RECRUITING | United States, Australia, Canada, France, Germany, Italy, South Korea | Hoffmann-La Roche |
| NCT07549412 | A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) | Phase 3 | RECRUITING | United States, Australia, Canada, China, Japan, South Korea, Taiwan | EMD Serono Research & Development Institute, Inc. |
| NCT02867397 | Study of Teysuno (S-1) Combined With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors | Phase 1 | COMPLETED | Non communiqué | Disphar International B.V. |
Publications liées
16 publication(s)Publications liées
16 publication(s)| Titre | PMID | DOI | Journal | Date |
|---|---|---|---|---|
| Single-Institution Outcomes of Neoadjuvant Gemcitabine and Nab-Paclitaxel Combination in Borderline Resectable Pancreatic Adenocarcinoma: A Three-Year Retrospective Audit. Voir source | 42291898 | 10.7759/cureus.108823 | Cureus | |
| Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network. Voir source | 42134356 | 10.1016/S0140-6736(26)00362-4 | Lancet (London, England) | |
| Bacterial Ghosts as Innovative Transport Vehicles for Platinum-Based Anticancer Drugs. Voir source | 42350154 | 10.1002/cmdc.70351 | ChemMedChem | |
| Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies. Voir source | 42322272 | 10.1080/2162402X.2026.2671491 | Oncoimmunology | |
| Insights into neuropathic pain: From disease models to therapeutic interventions. Voir source | 42498091 | 10.1016/j.neubiorev.2026.106878 | Neuroscience and biobehavioral reviews | |
| Domain-specific cognitive impairments following oxaliplatin and 5-fluorouracil treatment in rats: A preclinical study. Voir source | 42336324 | 10.1016/j.bbr.2026.116331 | Behavioural brain research | |
| Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer. Voir source | 42421558 | 10.1080/07853890.2026.2698360 | Annals of medicine | |
| Resveratrol Modulates Phosphatidylcholine Metabolism-Related Enzymes and Enhances Chemosensitivity in Colorectal Cancer Models. Voir source | 42589348 | 10.3390/ijms27156691 | International journal of molecular sciences | |
| Cost-effectiveness analysis of liposomal Irinotecan in combination with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas in Greece. Voir source | 42583863 | 10.1080/14737167.2026.2718413 | Expert review of pharmacoeconomics & outcomes research | |
| Salvage ultra-low-dose radiotherapy for conjunctival mantle cell lymphoma - a case report and literature review. Voir source | 42445702 | 10.5603/rpor.110467 | Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology | |
| Breakthrough reactions in pediatric chemotherapeutic desensitization: Outcomes and associated risk factors. Voir source | 42444056 | 10.1111/pai.70425 | Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology | |
| Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study. Voir source | 42422059 | 10.1136/bmjonc-2026-001085 | BMJ oncology | |
| Clinical use of trastuzumab combined with different chemotherapy regimens in multi-line treatment of advanced human epidermal growth factor receptor 2-positive gastric cancer: A case report. Voir source | 30214596 | 10.3892/ol.2018.9212 | Oncology letters | |
| Case Report: Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma. Voir source | 42415870 | 10.3389/fonc.2026.1722347 | Frontiers in oncology | |
| Gastric Cancer Treated with 5-Fluorouracil following Discontinuation of Adjuvant S1 plus Docetaxel and Capecitabine plus Oxaliplatin due to Drug-Induced Acute Pancreatitis: A Case Report. Voir source | 42416521 | 10.1159/000552401 | Case reports in oncology | |
| The Landmark Series: Neoadjuvant Therapy for Patients with Resectable Gastroesophageal Junction Adenocarcinomas. Voir source | 42414817 | 10.1245/s10434-026-20114-4 | Annals of surgical oncology |
Sources officielles
liens de rechercheDernière mise à jour des données : 2026-09-10
Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.